Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.68 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.53 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.51 |
| ▸ | PLK4 | O00444 | 1/20 | 0.49 |
| ▸ | PAK4 | O96013 | 1/20 | 0.49 |
| ▸ | PAK1 | Q13153 | 10/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17545983 | 1.00 | HPGDS (0.68) | HPGDSRPS6KB1PDPK1PLK4PAK4 | |
| SCHEMBL10227663 | 0.92 | HPGDS (0.74) | HPGDSRPS6KB1PDPK1PAK1GRIN2B | |
| SCHEMBL17545860 | 0.92 | HPGDS (0.74) | HPGDSRPS6KB1PDPK1PAK1GRIN2B | |
| Hydrochloric Acid SCHEMBL17527432 | 0.90 | HPGDS (0.72) | HPGDSRPS6KB1PDPK1PAK1GRIN2B | |
| SCHEMBL17545958 | 0.90 | HPGDS (0.76) | HPGDSRPS6KB1PDPK1PAK1GRIN2B | |
| Hydrochloric Acid SCHEMBL17527433 | 0.90 | HPGDS (0.72) | HPGDSRPS6KB1PDPK1PAK1GRIN2B | |
| SCHEMBL6128742 | 0.88 | HPGDS (0.71) | HPGDSPDPK1PAK1GRIN2BCYP2D6 | |
| SCHEMBL8291809 | 0.81 | HPGDS (1.00) | HPGDSPDPK1PAK1GRIN2BCYP2D6 | |
| SCHEMBL8291817 | 0.80 | HPGDS (0.97) | HPGDSPDPK1PAK1GRIN2BCYP2D6 | |
| SCHEMBL18466193 | 0.78 | HPGDS (0.69) | HPGDSRPS6KB1GRIN2BCYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. | 2017-02-02 | — | — | US | disclosed |
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. | 2017-02-02 | — | — | US | disclosed |
| US-9273028-B2 | Heterocyclic tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273028-B2 | Heterocyclic tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2016-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | TEC, ABL1, LCK | HPGDS 2389/4885RPS6KB1 867/4885PDPK1 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.